NEW HAVEN, Conn.--Jonathan Rothberg, chairman of the board of CuraGen, said he has begun a search for a president and chief executive officer for the company. "CuraGen has been experiencing tremendous growth through its recent collaborations, technological advancements, and scientific progress," Rothberg said. "Given our increasing momentum in the marketplace, I desire a partner at the helm of the company to complement my scientific skills as a leader of a large and rapidly growing business," he added. In the past year, the 300-person company, which was founded by Rothberg in 1993, has discovered more than 60,000 human genetic variations; signed a pharmacogenomics deal with Glaxo Wellcome; issued a patent on its GeneCalling technology; and announced a comprehensive product discovery and development collaboration with Hoffmann-La Roche.
CuraGen also recently appointed Richard Flavell, chairman and professor of immunobiology at Yale University, to its scientific advisory board. Flavell is also an investigator at Howard Hughes Medical Institute.